newsfilter
← Latest News
ACCESS Newswire·

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results

Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss improved 59% in Q4 2025